Astraveus Partners with NecstGen to Advance CAR-T Manufacturing
Astraveus Enters an Innovative Partnership
Astraveus SAS, a pioneering company in benchtop cell factory technology, is excited to announce a significant partnership with The Netherlands Center for the Clinical Advancement of Stem Cell and Gene Therapies, known as NecstGen. This collaboration focuses on evaluating the Lakhesys Benchtop Cell Factory™ for CAR-T therapy manufacturing, an area that holds great promise for advancing medical treatment.
Collaboration Goals and Objectives
The agreement with NecstGen centers around the manufacturing of CAR-T therapies, aiming to demonstrate how Astraveus' cutting-edge technology can drastically reduce costs while boosting efficiency. This partnership allows both organizations to leverage their strengths to create a more accessible and affordable method of producing CAR-T cells.
Technological Advancements with the Lakhesys System
Astraveus has recently made waves in the industry by successfully executing the first-ever end-to-end production of CAR-T cells within a microfluidic benchtop system. This groundbreaking achievement is now being put to the test on a wider scale, as the company begins external evaluations of its innovative manufacturing platform.
Significant Benefits of the Partnership
The unique microfluidic approach used in the Lakhesys Benchtop Cell Factory™ is designed to improve manufacturing processes significantly. By enhancing both cost-efficiency and throughput, Astraveus aims to set new industry benchmarks in the production of CAR-T therapies.
Leadership Insights
Jérémie Laurent, the CEO of Astraveus, expressed his enthusiasm for the partnership, stating, "NecstGen and Astraveus share a mutual goal of advancing cell and gene therapies, making them more accessible for patients. This collaboration with NecstGen allows us to showcase our technology in a transparent, cooperative environment. We are impressed with NecstGen's commitment to resolving current challenges in manufacturing cell therapies and are optimistic about the future benefits of our collaboration."
Transformative Technology
Similarly, Paul Bilars, the CEO of NecstGen, highlighted the potential of this partnership. He stated, "By aligning with leading innovators like Astraveus, we can deliver groundbreaking therapeutics to patients more efficiently. The unique manufacturing methods introduced by Astraveus have the potential to transform the landscape of CAR-T therapy development, facilitating faster and cost-effective solutions for these vital treatments."
Location and Impact
NecstGen operates out of the Leiden Bio Science Park, a prominent hub for life sciences in Europe. This location fosters a collaborative environment where academic and industrial therapy developers can transition promising research into effective patient treatments. The strategic partnership between NecstGen and Astraveus is expected to yield significant advancements in the field of cell therapies.
About Astraveus
Astraveus is a life science company based in Paris, committed to enhancing the quality of cell therapies while lowering production costs. Utilizing the groundbreaking Lakhesys Benchtop Cell Factory™, Astraveus is at the forefront of bioprocessing innovation, employing cutting-edge microfluidic technology to optimize processes from preclinical stages to commercial manufacturing. Established in 2016 by Jérémie Laurent at a leading hub for cell therapy, the company is dedicated to transforming the landscape of cell therapy development, making essential treatments accessible for all.
About NecstGen
NecstGen stands as a non-profit contract development and manufacturing organization, recognized for its excellence in Cell and Gene Therapy. Situated at the largest bio-cluster in the Netherlands, NecstGen offers indispensable development and manufacturing services to both academic and industrial developers, ultimately aimed at improving access to next-generation therapeutics.
Frequently Asked Questions
What is the purpose of the partnership between Astraveus and NecstGen?
The partnership aims to evaluate the manufacturing of CAR-T therapies using the Lakhesys Benchtop Cell Factory™, focusing on reducing costs and increasing efficiency.
What innovative technology is being used in CAR-T manufacturing?
Astraveus utilizes the Lakhesys Benchtop Cell Factory™ which employs microfluidic technology to optimize cell therapy production processes.
Where is NecstGen located?
NecstGen is located at the Leiden Bio Science Park, one of Europe’s largest life science clusters, facilitating collaboration in therapy development.
Who are the key leaders in this partnership?
Jérémie Laurent is the CEO of Astraveus, and Paul Bilars is the CEO of NecstGen, both of whom are leading this innovative initiative.
When was Astraveus founded?
Astraveus was founded in 2016, growing from a cell therapy research hub in Paris, aiming to revolutionize the accessibility of cell therapies.
About The Author
Contact Kelly Martin privately here. Or send an email with ATTN: Kelly Martin as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.
